Conditions: Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor
Interventions: Drug: Nivolumab
Sponsors: Instituto do Cancer do Estado de São Paulo; Financiadora de Estudos e Projetos
Recruiting
Feeds
32933 items (32933 unread) in 74 feeds
Acinar Cell Carcinoma
(534 unread)
Acinic Cell Carcinoma
(314 unread)
Adenoid Cystic Carcinoma
(566 unread)
Adrenal Gland Cancer
(2429 unread)
Ampulla Of Vater
(469 unread)
Anal Cancer
(2709 unread)
Angiosarcoma
(990 unread)
Appendix Cancer
(684 unread)
Bile Duct Cancer
(4355 unread)
Brain and CNS
(6120 unread)
Carcinoid
(887 unread)
Endocrine/Neuroendocrine
(5825 unread)
Gall Bladder Cancer
(1132 unread)
Hemangioendothelioma
(1176 unread)
Hepatoblastoma
(770 unread)
Pancreas
(563 unread)
Phyllodes
(384 unread)
PMP and Mucinous Tumors
(477 unread)
Rhabdomyosarcoma
(1118 unread)
Sarcoma
(1431 unread)
Trial - Cholangiocarcinoma (100 unread)
-
Agnostic Therapy in Rare Solid Tumors
Posted: October 14th, 2024, 11:00pm UTC
-
Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy
Posted: October 8th, 2024, 11:00pm UTC
Conditions: Hepatopancreaticobiliary (HPB) Malignancy; Gall Bladder Cancer; Bile Duct Cancer; Pancreatoduodenectomy; Hepatectomy
Interventions: Other: Hepatopancreatoduodenectomy
Sponsors: Seoul National University Hospital
Completed -
Liver Cancer Investigation for Prognosis Study
Posted: October 2nd, 2024, 11:00pm UTC
Conditions: Liver Neoplasms
Sponsors: Sun Yat-sen University
Not yet recruiting -
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Posted: October 1st, 2024, 11:00pm UTC
Conditions: Biliary Tract Cancer (BTC)
Interventions: Drug: D07001-Softgel Capsules; Drug: Placebo; Combination Product: Capecitabine
Sponsors: InnoPharmax Inc.
Not yet recruiting -
Adebrelimab Combined With Capecitabine for Adjuvant Therapy in Cholangiocarcinoma With High-risk Recurrence Post-surgery
Posted: September 23rd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma Cancer; Adebrelimab (SHR-1316)
Interventions: Drug: Adebrelimab and capecitabine; Drug: capecitabine
Sponsors: The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting -
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 R132 Mutation After At Least One Prior Systemic Treatment - an Observational Study
Posted: September 23rd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Sponsors: iOMEDICO AG; Servier Deutschland GmbH
Not yet recruiting -
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Posted: September 23rd, 2024, 11:00pm UTC
Conditions: Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor
Interventions: Drug: LY4066434.; Drug: Cetuximab; Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Leucovorin; Drug: Irinotecan; Drug: 5Fluorouracil; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pembrolizumab
Sponsors: Eli Lilly and Company
Not yet recruiting -
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients
Posted: September 4th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: HNF4α srRNA
Sponsors: Shanghai Changzheng Hospital
Not yet recruiting -
The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma
Posted: August 27th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Genetic: Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)
Sponsors: Shanghai Changzheng Hospital
Not yet recruiting -
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
Posted: August 26th, 2024, 11:00pm UTC
Conditions: Pancreatic Cancer; Cholangiocarcinoma; Intraductal Papillary Mucinous Neoplasm; Neuroendocrine Tumor; Solid Pseudopapillary Tumor
Interventions: Dietary Supplement: oral protein supplements; Genetic: placebo
Sponsors: Yonsei University
Completed -
Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA
Posted: August 26th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma Resectable
Interventions: Drug: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
Sponsors: University Health Network, Toronto; Sunnybrook Health Sciences Centre; Hamilton Health Sciences Corporation
Not yet recruiting -
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
Posted: August 22nd, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma; Chemotherapy Effect; Immunotherapy
Interventions: Drug: Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody
Sponsors: Third Affiliated Hospital, Sun Yat-Sen University; Second Affiliated Hospital of Guangzhou Medical University
Not yet recruiting -
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Posted: August 7th, 2024, 11:00pm UTC
Conditions: Hepatocholangiocarcinoma; Fibrolamellar Carcinoma; Hepatic Epithelioid Hemangioendothelioma; Hepatoblastoma; Hepatic Neuroendocrine Carcinoma; Hepatic Carcinosarcomas; Hepatic Cystadenoma; Hepatic Leiomyosarcomas; Hepatic Angiosarcomas; Cholangiocarcinoma
Sponsors: Federation Francophone de Cancerologie Digestive; Société Nationale Française de Gastroentérologie
Recruiting -
Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma
Posted: August 6th, 2024, 11:00pm UTC
Conditions: Living Donor Liver Transplantation; Liver Transplantation; Neoadjuvant Therapy
Interventions: Procedure: Living donor liver transplantation
Sponsors: Jena University Hospital
Not yet recruiting -
Impact of Preoperative Endoscopic Ultrasound-guided Fine-needle Aspiration in Cholangiocarcinoma Patients
Posted: August 2nd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma Patients
Interventions: Diagnostic Test: Endoscopic ultrasound-guided fine-needle aspiration
Sponsors: Asian Institute of Gastroenterology, India
Not yet recruiting -
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Posted: July 31st, 2024, 11:00pm UTC
Conditions: Biliary Tract Carcinoma; Cholangiocarcinoma
Interventions: Drug: Pemigatinib and Durvalumab
Sponsors: Eastern Hepatobiliary Surgery Hospital
Not yet recruiting -
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Posted: July 31st, 2024, 11:00pm UTC
Conditions: Biliary Tract Cancer
Interventions: Drug: Ivonescimab; Drug: FOLFOX regimen
Sponsors: UNICANCER; Cancer Research UK & UCL Cancer Trials Centre; Belgian Group of Digestive Oncology; Summit Therapeutics
Not yet recruiting -
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Posted: July 25th, 2024, 11:00pm UTC
Conditions: Advanced Solid Tumor
Interventions: Drug: Neratinib tablets
Sponsors: Convalife (Shanghai) Co., Ltd.
Not yet recruiting -
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Posted: July 18th, 2024, 11:00pm UTC
Conditions: Advanced/Metastatic Cancer
Interventions: Drug: futibatinib; Drug: futibatinib, fulvestrant
Sponsors: Taiho Oncology, Inc.
Enrolling by invitation -
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
Posted: July 17th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine-Oxaliplatin Regimen
Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting -
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Posted: July 16th, 2024, 11:00pm UTC
Conditions: Pancreatic Ductal Adenocarcinoma; Cholangiocarcinoma; Gastric Cancer; Bladder Cancer; Hepatocellular Carcinoma; Pheochromocytoma; Ovarian Cancer
Interventions: Drug: [18F]FAPI-74; Drug: [18F]FDG
Sponsors: National Cancer Institute (NCI)
Not yet recruiting -
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Posted: July 15th, 2024, 11:00pm UTC
Conditions: Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Interventions: Drug: Ivosidenib; Drug: Durvalumab (for the first 8, 21-day, cycles); Drug: Gemcitabine (for the first 8, 21-day, cycles); Drug: Cisplatin (for the first 8, 21-day, cycles); Drug: Durvalumab (starting from cycle 9); Drug: Ivosidenib Recommended Combination Dose (RCD)
Sponsors: Institut de Recherches Internationales Servier
Not yet recruiting -
Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)
Posted: July 15th, 2024, 11:00pm UTC
Conditions: Biliary Tract Cancer
Interventions: Radiation: Consolidative radiotherapy; Drug: Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
Sponsors: Shanghai Zhongshan Hospital
Not yet recruiting -
Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma
Posted: July 10th, 2024, 11:00pm UTC
Conditions: Klatskin Tumor
Interventions: Radiation: Stereotactic body radiation therapy
Sponsors: Erasmus Medical Center; Dutch Cancer Society
Recruiting -
Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin
Posted: July 8th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma; Chemotherapy Effect; Immunotherapy
Interventions: Drug: OBI-833/OBI-821
Sponsors: Chang Gung Memorial Hospital
Not yet recruiting -
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
Posted: July 4th, 2024, 11:00pm UTC
Conditions: Hepatocellular Carcinoma Non-resectable; Cholangiocarcinoma Non-resectable; Liver Metastases; Liver Malignant Tumors
Interventions: Procedure: TACE with ICI
Sponsors: Tianjin Medical University Cancer Institute and Hospital
Recruiting -
Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)
Posted: June 25th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Other: Non-Interventional Study
Sponsors: Mayo Clinic
Enrolling by invitation -
A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
Posted: June 21st, 2024, 11:00pm UTC
Conditions: Solid Tumor
Interventions: Drug: LB1410; Drug: LB4330
Sponsors: L & L biopharma Co., Ltd., Shanghai China; Shanghai East Hospital
Recruiting -
Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma
Posted: June 17th, 2024, 11:00pm UTC
Conditions: Overall Survival; Disease-free Survival
Interventions: Procedure: Microwave ablation (MWA) versus Liver Resection (LR)
Sponsors: Chinese PLA General Hospital
Recruiting -
Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents
Posted: June 11th, 2024, 11:00pm UTC
Conditions: Pancreatic Cancer Non-resectable; Bile Duct Cancer; Papillary Carcinoma; Duodenal Cancer
Interventions: Procedure: Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction.; Procedure: Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction.; Procedure: Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.
Sponsors: Region Stockholm
Recruiting -
Combining Chemoradiotherapy With Sintilimab in First-Line ICC
Posted: June 7th, 2024, 11:00pm UTC
Conditions: ICC
Interventions: Radiation: radiotherapy; Drug: gemcitabine + cisplatin; Drug: slulimumab
Sponsors: Shanghai Zhongshan Hospital
Not yet recruiting -
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Posted: June 4th, 2024, 11:00pm UTC
Conditions: Extrahepatic Cholangiocarcinoma; Unresectable Perihilar or Ductal CCA
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Durvalumab; Procedure: ID-RFA
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Universitätsklinikum Düsseldorf, Germany; Universitätsklinikum Köln, Germany; AstraZeneca
Recruiting -
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Posted: June 4th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: Olaparib
Sponsors: Australasian Gastro-Intestinal Trials Group; Wayne Elphinstone Research Fund; AstraZeneca
Not yet recruiting -
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
Posted: June 3rd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Combination Product: Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil
Sponsors: West China Hospital
Not yet recruiting -
INSPIRE: A Multi-Cancer Early Detection Study
Posted: June 3rd, 2024, 11:00pm UTC
Conditions: Lung Cancer; Gastric Cancer; Liver Cancer; Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Breast Cancer; Cervical Cancer; Ovarian Cancer; Endometrial Cancer; Bladder Cancer; Prostate Cancer; Cholangiocarcinoma
Sponsors: Singlera Genomics Inc.; Fudan University; Hubei Cancer Hospital, Huazhong University of Science and Technology; China-Japan Friendship Hospital; Shanxi Provincial Cancer Hospital; Xuhui Central Hospital, Fudan University; Shanghai Electric Power Hospital; East Hospital, Tongji University; The First Affiliated Hospital of Xi' an Jiaotong University; GaoZhou People's Hosipital; Anhui Provincial Hospital; Beijing Friendship Hospital
Not yet recruiting -
Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
Posted: June 3rd, 2024, 11:00pm UTC
Conditions: Advanced Cholangiocarcinoma; FGFR2 Fusion
Interventions: Drug: Pemigatinib; Drug: Atezolizumab; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; Incyte Corporation; Genentech, Inc.
Not yet recruiting -
Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma
Posted: May 30th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Radiation: Proton Beam Therapy; Drug: Concurrent oral capecitabine chemotherapy; Drug: Cisplatin & Gemcitabine intravenous chemotherapy; Procedure: Orthotropic Liver Transplant
Sponsors: The Christie NHS Foundation Trust; University College London Hospitals; University College, London; Royal Free Hospital NHS Foundation Trust
Not yet recruiting -
hepatomiR cACLD Study
Posted: May 29th, 2024, 11:00pm UTC
Conditions: Chronic Liver Disease and Cirrhosis; Chronic Liver Disease; Portal Hypertension
Interventions: Diagnostic Test: hepatomiR
Sponsors: Karl Landsteiner University of Health Sciences; University Hospital St. Pölten
Recruiting -
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Posted: May 20th, 2024, 11:00pm UTC
Conditions: Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Refractory Cholangiocarcinoma; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Heat Shock Factor 1 Pathway Inhibitor NXP800; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Procedure: Ultrasound-Guided Biopsy
Sponsors: Mayo Clinic
Recruiting -
Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma
Posted: May 16th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Lenvatinib
Sponsors: Zhiyong Huang
Not yet recruiting -
Diagnostic Approach for Cholangiocarcinoma Using Liquid Bile Biopsy
Posted: May 16th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Diagnostic Test: Proteomic profile
Sponsors: University Hospital, Bordeaux
Not yet recruiting -
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
Posted: May 9th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Combination Product: Neoantigen Vaccine plus Capecitabine
Sponsors: Yongyi Zeng
Not yet recruiting -
A Prospective, Single-arm, Multicenter Phase II Clinical Study of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
Posted: May 8th, 2024, 11:00pm UTC
Conditions: Adebrelimab; Hepatocellular Carcinoma
Interventions: Drug: Adebrelimab
Sponsors: Tianjin Medical University Cancer Institute and Hospital
Recruiting -
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Posted: May 6th, 2024, 11:00pm UTC
Conditions: Colorectal Cancer; Cholangiocarcinoma; Appendiceal Adenocarcinoma; Pancreatic Adenocarcinoma; Gastric Adenocarcinoma; Endometrial Adenocarcinoma; Triple Negative Breast Cancer; Ovarian Cancer; Prostate Cancer
Interventions: Drug: APL-5125
Sponsors: Apollo Therapeutics Ltd
Recruiting -
Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma
Posted: April 25th, 2024, 11:00pm UTC
Conditions: Bile Duct Adenocarcinoma Non-Resectable; HER2 Gene Mutation
Interventions: Drug: Disitamab Vedotin Plus Cadonilimab
Sponsors: Zhejiang Cancer Hospital
Recruiting -
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma
Posted: April 24th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma Resectable; Cholangiocarcinoma; Liver
Interventions: Diagnostic Test: LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
Sponsors: City of Hope Medical Center
Recruiting -
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
Posted: April 19th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Radiation: radioembolization with Y-90; Drug: Durvalumab; Drug: Cisplatin; Drug: Gemcitabine
Sponsors: Francesco De Cobelli; Cardarelli Hospital; A.O. Ospedale Papa Giovanni XXIII; AOU Pisana, Pisa, Italy
Recruiting -
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Posted: April 19th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Adebrelimab
Sponsors: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting -
First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC
Posted: April 17th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Radiation: Radiotherapy; Drug: HAIC (GEMOX); Drug: Chemotherapy
Sponsors: Shandong Cancer Hospital and Institute
Recruiting -
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
Posted: April 17th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Procedure: Resection/Ablation of tumor; Procedure: Palliative chemotherapy; Procedure: Neoadjuvant chemotherapy; Procedure: Stereotatic radiotherapy; Procedure: Best supportive care
Sponsors: Rigshospitalet, Denmark
Recruiting -
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
Posted: April 17th, 2024, 11:00pm UTC
Conditions: Advanced Solid Tumors; Cholangiocarcinoma
Interventions: Drug: Tinengotinib
Sponsors: TransThera Sciences (Nanjing), Inc.
Available -
Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures
Posted: April 17th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma; Biliary Stricture
Sponsors: Soonchunhyang University Hospital
Not yet recruiting -
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Posted: April 12th, 2024, 11:00pm UTC
Conditions: Lung Cancer; Breast Cancer; Colorectal Cancer; Thyroid Cancer; Gastric Cancer; Cervical Cancer; Liver Cancer; Pancreatic Cancer; Cholangiocarcinoma; Prostate Cancer; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma
Sponsors: Beijing Friendship Hospital
Recruiting -
EchoTip AcuCore Post-Market Clinical Study
Posted: April 10th, 2024, 11:00pm UTC
Conditions: Adenocarcinoma; Neuroendocrine Tumors; Hepatocellular Carcinoma; Cholangiocarcinoma; Malignant Lymphoma; Metastasis; Chronic Pancreatitis; Autoimmune Pancreatitis
Interventions: Device: EchoTip AcuCore
Sponsors: Cook Research Incorporated
Recruiting -
Extent of Intrahepatic Infiltration of PHCC
Posted: April 10th, 2024, 11:00pm UTC
Conditions: Perihilar Cholangiocarcinoma
Sponsors: Beijing Tsinghua Chang Gung Hospital
Completed -
The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Posted: April 9th, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Drug: [18F]F-FAPI PET-CT
Sponsors: Mara Veenstra, MD; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); UMC Utrecht
Not yet recruiting -
Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma
Posted: April 2nd, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma
Interventions: Drug: Durvalumab 1120 mg; Drug: Durvalumab 1500 mg; Drug: Tremelimumab i.v. at 300 mg; Combination Product: Cisplatin (CDDP) 25 mg/mq i.v; Combination Product: Gemcitabine (GEM) 1000 mg/mq i.v.
Sponsors: National Cancer Institute, Naples
Recruiting -
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Posted: April 2nd, 2024, 11:00pm UTC
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Primary Liver Cancer; Primary Liver Carcinoma; Hepatic Cancer; Hepatic Carcinoma
Interventions: Diagnostic Test: ELUCIDATE
Sponsors: City of Hope Medical Center
Recruiting -
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Posted: April 1st, 2024, 11:00pm UTC
Conditions: Cholangiocarcinoma; Multiple Myeloma; Colon Cancer; Rectal Cancer
Interventions: Other: Return of Genetic Results: Biomarker information from cancer cells; Other: Return of Genetic Results: Inherited mutations related to cancer; Other: Return of Genetic Results: Inherited mutations related to other medical issues
Sponsors: Washington University School of Medicine; National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital
Recruiting -
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
Posted: April 1st, 2024, 11:00pm UTC
Conditions: Pancreatic Disease; Pancreatic Cancer; Pancreatic Cyst; Gastrointestinal Tumor; Bile Duct Diseases; Bile Duct Cancer; Lymph Node Disease; Submucosal Tumor of Gastrointestinal Tract; Gastrointestinal Cancer
Interventions: Device: Endoscopic ultrasound examination
Sponsors: Orlando Health, Inc.
Recruiting -
HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC
Posted: March 28th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: HAIC-GEMOX+Cadonilimab+Regorafenib
Sponsors: Fudan University
Recruiting -
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Posted: March 28th, 2024, 11:00pm UTC
Conditions: Solid Tumor
Interventions: Drug: ACTM-838
Sponsors: Actym Therapeutics, Inc.
Recruiting -
A Single Center, Retrospective Clinical Study on the Clinical Characteristics of Primary Liver Cancer
Posted: March 22nd, 2024, 11:00pm UTC
Conditions: Primary Liver Cancer
Sponsors: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recruiting -
HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
Posted: March 15th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma; Chemotherapy Effect
Interventions: Drug: Floxuridine; Procedure: Selective Internal Radiation Therapy (SIRT)
Sponsors: Oslo University Hospital
Recruiting -
Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma
Posted: March 15th, 2024, 11:00pm UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Surufatinibã€Toripalimabã€Gemcitabineã€Oxaliplatin
Sponsors: Fudan University
Not yet recruiting -
Open Versus Laparoscopic Ablation of Liver Malignancies
Posted: March 12th, 2024, 11:00pm UTC
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Liver Metastases
Interventions: Procedure: Laparoscopic ablation; Procedure: Open ablation
Sponsors: Rigshospitalet, Denmark
Recruiting -
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Posted: March 12th, 2024, 11:00pm UTC
Conditions: Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma
Interventions: Drug: Afatinib; Drug: Pemigatinib
Sponsors: Massachusetts General Hospital; Boehringer Ingelheim; Incyte Corporation
Recruiting -
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Posted: March 7th, 2024, 1:00am UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab
Sponsors: Nanfang Hospital, Southern Medical University
Recruiting -
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
Posted: March 6th, 2024, 1:00am UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: HAIC; Drug: Adebrelimab; Drug: Apatinib
Sponsors: Lei ZHAO
Recruiting -
A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma
Posted: March 4th, 2024, 1:00am UTC
Conditions: Intrahepatic Cholangiocarcinoma; Machine Learning
Interventions: Procedure: lymph nodes dissection
Sponsors: West China Hospital
Recruiting -
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy
Posted: March 4th, 2024, 1:00am UTC
Conditions: Metastatic Colorectal Cancer; Pancreas Adenocarcinoma; Cholangiocarcinoma
Interventions: Diagnostic Test: Multiplex PCR-test for circulating tumor DNA
Sponsors: Oslo University Hospital
Recruiting -
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Fetched: February 29th, 2024, 3:01am UTC
Conditions: Metastatic Cancer; Solid Tumor
Interventions: Drug: Sym021; Drug: Sym022; Drug: Sym023; Drug: Irinotecan Hydrochloride
Sponsors: Symphogen A/S
Completed -
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
Posted: February 29th, 2024, 1:00am UTC
Conditions: Primary Sclerosing Cholangitis; Inflammatory Bowel Diseases
Interventions: Biological: Faecal Microbiota Transplant; Other: FMT Placebo
Sponsors: University of Birmingham; PSC Support; Life Arc
Recruiting -
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
Posted: February 28th, 2024, 1:00am UTC
Conditions: Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
Interventions: Drug: Adebrelimab, Apatinib, Gemcitabine, cisplatin
Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting -
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
Posted: February 28th, 2024, 1:00am UTC
Conditions: Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)
Interventions: Drug: Allogeneic NK（CCT-ANK-11)
Sponsors: Beijing Kejing Biotechnology Co., Ltd.
Withdrawn -
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Posted: February 28th, 2024, 1:00am UTC
Conditions: Biliary Tract Cancer; HER2 Gene Mutation
Interventions: Drug: Zanidatamab; Drug: Cisplatin; Drug: Gemcitabine; Drug: Pembrolizumab; Drug: Durvalumab
Sponsors: Jazz Pharmaceuticals
Recruiting -
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
Posted: February 26th, 2024, 1:00am UTC
Conditions: Biliary Stricture; Bile Duct Cancer; Pancreas Cancer
Sponsors: Peking University Third Hospital; Beijing Tsinghua Changgeng Hospital
Recruiting -
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Posted: February 23rd, 2024, 1:00am UTC
Conditions: Bile Duct Cancer
Interventions: Drug: Gemcitabin, Cisplatin and Durvalumab; Procedure: Biliary Radiofrequency Ablation; Procedure: Endoscopic Retrograde Cholangio-Pancreatography with stenting
Sponsors: Insel Gruppe AG, University Hospital Bern; Swiss Cancer League
Not yet recruiting -
Targeted Navigation in Hepatocellular Carcinoma (HCC)
Posted: February 15th, 2024, 1:00am UTC
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatobiliary Cancer
Interventions: Behavioral: Target Navigation Pilot Program
Sponsors: University of Miami; The V Foundation
Recruiting -
MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers
Posted: February 14th, 2024, 1:00am UTC
Conditions: Pancreatic Cancer; Cholangiocarcinoma; Ampullary Cancer; Biliary Stricture; Gallstone Disease
Interventions: Diagnostic Test: Small RNA Sequencing and Validation of candidate miRNAs
Sponsors: Imperial College London; Royal Surrey County Hospital NHS Foundation Trust; Royal Free Hospital NHS Foundation Trust
Completed -
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
Posted: February 13th, 2024, 1:00am UTC
Conditions: Malignant Mesothelioma; Colorectal Cancer; Bile Duct Cancer; Rectal Cancer; Ovary Cancer; Pancreatic Cancer; Breast Cancer Female
Interventions: Biological: UCMYM802 Injection
Sponsors: UTC Therapeutics Inc.; Peking University Cancer Hospital & Institute
Recruiting -
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
Posted: February 2nd, 2024, 1:00am UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: HAIC+TAE; Drug: Tislelizumab; Drug: Surufatinib
Sponsors: Qilu Hospital of Shandong University; BeiGene
Recruiting -
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Posted: February 2nd, 2024, 1:00am UTC
Conditions: Solid Tumor
Interventions: Drug: ZG005 Powder for Injection; Drug: Donafenib Tosilate Tablets
Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Recruiting -
Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma
Posted: January 25th, 2024, 1:00am UTC
Conditions: Biliary Tract Cancer; Portal Vein Embolization
Interventions: Procedure: Potal vein embilization
Sponsors: Seoul National University Hospital
Completed -
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors：NEO-ERA-01 Study
Posted: January 17th, 2024, 1:00am UTC
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Adebrelimab; Drug: Lenvatinib; Drug: Gemcitabine; Drug: Oxaliplatin
Sponsors: The First Affiliated Hospital with Nanjing Medical University; Jiangsu Hengrui Pharmaceutical Co., Ltd.
Recruiting -
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Posted: January 10th, 2024, 1:00am UTC
Conditions: Pancreatic Adenocarcinoma; Cholangiocarcinoma; Lung Cancer; Stomach Cancer; Esophageal Carcinoma; Breast Cancer
Interventions: Drug: Paclitaxel Polymeric Micelles for Injection
Sponsors: Liu Huang
Recruiting -
A RCT of Low MBO Drainage Strategies
Posted: January 9th, 2024, 1:00am UTC
Conditions: Jaundice, Obstructive; Cholangiopancreatography, Endoscopic Retrograde; Endoscopic Ultrasound-Guided Drainage
Interventions: Procedure: EUS-BD; Procedure: ERCP-BD
Sponsors: Peking Union Medical College Hospital
Recruiting -
Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer
Posted: January 9th, 2024, 1:00am UTC
Conditions: Pancreatic Cancer; Advanced Biliary Cancer
Interventions: Drug: anti-EX02 CAR T cells
Sponsors: Zhang Xiaofeng,MD; Zeno Therapeutics Pte. Ltd
Not yet recruiting -
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
Posted: January 8th, 2024, 1:00am UTC
Conditions: Cholangiocarcinoma Non-resectable
Interventions: Procedure: drug eluting beads-transcatheter arterial chemoembolization; Drug: envatinib plus anti-PD(L)1
Sponsors: Ze-yang Ding, MD; Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)
Recruiting -
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Posted: January 5th, 2024, 1:00am UTC
Conditions: Cholangiocarcinoma Non-resectable
Interventions: Procedure: HAIC; Drug: Lenvatinib plus pucotenlimab
Sponsors: Ze-yang Ding, MD; Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer
Recruiting -
Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Posted: January 5th, 2024, 1:00am UTC
Conditions: Cholangiocarcinoma Non-resectable
Interventions: Procedure: DEB-TACE; Drug: Lenvatinib plus pucotenlimab
Sponsors: Tongji Hospital; Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)
Recruiting -
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
Posted: December 21st, 2023, 1:00am UTC
Conditions: Biliary Tract Cancer; HER2 Gene Mutation
Interventions: Drug: SOC plus trastuzumab and pembrolizumab
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel; MSD Sharp & Dohme GmbH, Germany
Recruiting -
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
Posted: December 21st, 2023, 1:00am UTC
Conditions: Locally Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Recurrent Cholangiocarcinoma; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Sacituzumab Govitecan
Sponsors: University of Kansas Medical Center; National Cancer Institute (NCI)
Recruiting -
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
Posted: December 19th, 2023, 1:00am UTC
Conditions: Cholangiocarcinoma; Klatskin Tumor; Bile Duct Cancer; Liver Cancer
Interventions: Procedure: Intraductal biliary radiofrequency ablation
Sponsors: Universitätsklinikum Hamburg-Eppendorf
Not yet recruiting -
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
Posted: December 13th, 2023, 1:00am UTC
Conditions: Biliary Tract Carcinoma; Radiotherapy; Radio-frequency Ablation
Interventions: Procedure: ID-RFA and Radiotherapy
Sponsors: National Cancer Center, Korea; Boston Scientific Corporation
Not yet recruiting -
Congenital Biliary Dilatation Diagnosis Based on 3D Morphological Characteristics
Posted: December 8th, 2023, 1:00am UTC
Conditions: Congenital Biliary Dilatation
Interventions: Other: Contrast-enhanced computed tomography (CECT) and 3D morphological analysis
Sponsors: Tsinghua University; Beijing Tsinghua Chang Gung Hospital
Completed -
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Posted: December 7th, 2023, 1:00am UTC
Conditions: Locally Advanced Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Solid Tumor; Metastatic Cholangiocarcinoma
Interventions: Drug: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles; Drug: Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Sponsors: Tyra Biosciences, Inc
Recruiting -
Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma
Posted: November 24th, 2023, 1:00am UTC
Conditions: Liver Cancer
Interventions: Other: phenotyping
Sponsors: Inserm U955
Recruiting -
Liver Transplantation in Intrahepatic Cholangiocarcinoma
Posted: November 20th, 2023, 1:00am UTC
Conditions: Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma, Intrahepatic
Interventions: Procedure: Liver Transplant
Sponsors: Rutgers, The State University of New Jersey
Recruiting -
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Posted: November 16th, 2023, 1:00am UTC
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Gallbladder Cancer; Surufatinib; Angiogenesis Inhibitors; Tislelizumab; Antineoplastic Agents, Immunological; Immunotherapy
Interventions: Drug: HAIC; Drug: Surufatinib; Drug: Tislelizumab
Sponsors: Wuhan Union Hospital, China
Not yet recruiting